# Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Metabolism of a Single Dose of Licarbazepine

> **NCT00424671** · PHASE1 · COMPLETED · sponsor: **Novartis** · enrollment: 16 (—)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Licarbazepine

## Key facts

- **NCT ID:** NCT00424671
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 16 (—)
- **Last updated:** 2007-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00424671

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00424671, "Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Metabolism of a Single Dose of Licarbazepine". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00424671. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*